NASDAQ:ILMN - Illumina Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $374.50
  • Forecasted Upside: -20.17 %
  • Number of Analysts: 17
  • Breakdown:
  • 4 Sell Ratings
  • 7 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +3.44 (0.74%)

This chart shows the closing price for ILMN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Illumina Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ILMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ILMN

Analyst Price Target is $374.50
▼ -20.17% Downside Potential
This price target is based on 17 analysts offering 12 month price targets for Illumina in the last 3 months. The average price target is $374.50, with a high forecast of $570.00 and a low forecast of $280.00. The average price target represents a -20.17% upside from the last price of $469.13.

This chart shows the closing price for ILMN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 17 polled investment analysts is to hold stock in Illumina. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 4 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 4 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 4 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 4 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 4 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 4 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 4 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 4 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/28/2021Wells Fargo & CompanyBoost Price TargetUnderweight$330.00 ➝ $340.00High
4/28/2021Canaccord GenuityBoost Price TargetBuy$460.00 ➝ $470.00Medium
4/6/2021Wells Fargo & CompanyBoost Price TargetUnderweight$300.00 ➝ $330.00Medium
4/6/2021Canaccord GenuityBoost Price TargetBuy$445.00 ➝ $460.00Low
3/31/2021Canaccord GenuityUpgradeHold ➝ Buy$410.00 ➝ $445.00High
3/31/2021Atlantic SecuritiesDowngradeOverweight ➝ Neutral$390.00High
3/2/2021BarclaysInitiated CoverageUnderweight$325.00High
2/16/2021BTIG ResearchBoost Price TargetBuy$410.00 ➝ $570.00Low
2/12/2021Canaccord GenuityBoost Price TargetHold$350.00 ➝ $410.00Low
2/12/2021Piper SandlerBoost Price TargetOverweight$415.00 ➝ $510.00Low
2/12/2021CowenBoost Price TargetOutperform$385.00 ➝ $460.00Low
2/12/2021SVB LeerinkBoost Price TargetOutperform$360.00 ➝ $470.00Low
12/22/2020OTR GlobalUpgradePositiveMedium
12/22/2020Piper SandlerUpgradeNeutral ➝ Overweight$340.00 ➝ $415.00Medium
12/17/2020BTIG ResearchUpgradeNeutral ➝ Buy$410.00Medium
12/16/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$330.00 ➝ $335.00Low
12/16/2020Smith Barney CitigroupBoost Price Target$330.00 ➝ $335.00Low
12/7/2020SVB LeerinkBoost Price TargetPositive ➝ Outperform$325.00 ➝ $360.00Low
12/1/2020ArgusLower Price Target$380.00 ➝ $355.00Low
10/30/2020SVB LeerinkBoost Price TargetOutperform$315.00 ➝ $325.00High
10/13/2020GuggenheimDowngradeBuy ➝ NeutralMedium
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$355.00 ➝ $355.00Medium
9/29/2020Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
9/22/2020Canaccord GenuityLower Price TargetHold$350.00 ➝ $300.00Low
9/22/2020Robert W. BairdLower Price TargetNeutral$335.00 ➝ $281.00Low
9/22/2020SVB LeerinkLower Price TargetOutperform$360.00 ➝ $315.00Low
9/22/2020Stifel NicolausDowngradeBuy ➝ Hold$380.00 ➝ $280.00Low
9/22/2020UBS GroupDowngradeBuy ➝ Neutral$390.00 ➝ $285.00Low
9/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$390.00 ➝ $280.00Low
9/21/2020GuggenheimUpgradeNeutral ➝ Buy$345.00High
9/11/2020ArgusReiterated RatingBuy ➝ Reduce$380.00 ➝ $380.00Low
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$400.00Low
8/7/2020SVB LeerinkLower Price TargetOutperform$370.00 ➝ $360.00High
8/7/2020Evercore ISIDowngradeIn-Line ➝ Underperform$310.00High
8/7/2020Piper SandlerDowngradeOverweight ➝ Neutral$356.00 ➝ $340.00High
7/7/2020GuggenheimDowngradeBuy ➝ NeutralLow
7/2/2020JPMorgan Chase & Co.Boost Price TargetOverweight$340.00 ➝ $390.00Low
5/21/2020ArgusBoost Price Target$340.00 ➝ $380.00Low
5/1/2020Piper SandlerLower Price TargetPositive ➝ Overweight$370.00 ➝ $356.00Low
5/1/2020Wells Fargo & CompanyBoost Price TargetUnderweight$245.00 ➝ $290.00Low
5/1/2020Stifel NicolausBoost Price TargetBuy$298.00 ➝ $325.00High
5/1/2020CowenBoost Price TargetOutperform$275.00 ➝ $320.00Medium
4/24/2020CitigroupDowngradeBuy ➝ Neutral$250.00 ➝ $320.00Low
4/21/2020Robert W. BairdDowngradeOutperform ➝ Neutral$310.00High
4/15/2020Robert W. BairdLower Price TargetOutperform ➝ Outperform$339.00 ➝ $310.00Medium
4/2/2020Stifel NicolausLower Price TargetBuy$345.00 ➝ $298.00Medium
3/30/2020Wells Fargo & CompanyLower Price TargetUnderweight$290.00 ➝ $245.00Medium
3/26/2020BarclaysLower Price TargetOverweight$390.00 ➝ $350.00High
3/20/2020CitigroupLower Price TargetBuy$350.00 ➝ $250.00Low
2/4/2020Credit Suisse GroupReiterated RatingBuy$340.00Low
1/30/2020Wells Fargo & CompanyLower Price TargetUnderweight$300.00 ➝ $290.00Low
1/30/2020CitigroupLower Price TargetBuy$385.00 ➝ $350.00High
1/9/2020Piper SandlerBoost Price TargetOverweight$341.00 ➝ $370.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageUnderweight$300.00Medium
1/6/2020CitigroupInitiated CoverageBuy$385.00Low
1/3/2020UBS GroupUpgradeNeutral ➝ Buy$355.00Medium
12/18/2019CowenReiterated RatingOutperform$320.00 ➝ $335.00Medium
11/14/2019Stifel NicolausInitiated CoverageBuy$345.00Medium
10/25/2019CowenSet Price TargetBuy$320.00Low
10/25/2019Wolfe ResearchSet Price TargetBuy$380.00N/A
10/25/2019Piper Jaffray CompaniesLower Price TargetOverweight$348.00 ➝ $341.00High
10/25/2019GuggenheimInitiated CoverageBuy ➝ Buy$350.00 ➝ $350.00High
9/27/2019Piper Jaffray CompaniesSet Price TargetBuy$348.00Medium
9/25/2019ArgusBoost Price TargetBuy$300.00 ➝ $340.00Medium
7/31/2019Credit Suisse GroupReiterated RatingBuy$340.00Medium
7/30/2019UBS GroupBoost Price TargetBuy$350.00 ➝ $355.00Low
7/30/2019Piper Jaffray CompaniesLower Price TargetOverweight$382.00 ➝ $348.00Low
7/30/2019Canaccord GenuityDowngradeBuy ➝ Hold$330.00 ➝ $300.00Medium
7/18/2019ArgusLower Price TargetBuy$340.00Low
7/12/2019CowenLower Price TargetOutperform$380.00 ➝ $320.00Low
7/12/2019Canaccord GenuityLower Price TargetBuy$377.00 ➝ $330.00High
7/12/2019Deutsche Bank AktiengesellschaftLower Price TargetHold$290.00 ➝ $280.00High
7/12/2019Bank of AmericaDowngradeBuy ➝ Underperform$310.00High
6/10/2019Canaccord GenuityReiterated RatingBuy$350.00 ➝ $360.00Low
5/30/2019Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
4/26/2019Canaccord GenuityReiterated RatingBuy$360.00 ➝ $350.00Medium
4/2/2019OTR GlobalDowngradePositiveLow
1/30/2019Bank of AmericaReiterated RatingBuy$355.00Low
1/30/2019SVB LeerinkUpgradeOutperform$380.00 ➝ $365.00High
1/25/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$296.53Medium
1/7/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$320.00 ➝ $288.00Medium
1/3/2019UBS GroupUpgradeNeutral ➝ Buy$340.00 ➝ $370.00High
10/24/2018BarclaysBoost Price TargetOverweight ➝ Overweight$350.00 ➝ $370.00High
10/12/2018Deutsche Bank AktiengesellschaftBoost Price TargetBuy$350.00Low
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$340.00Low
10/2/2018Piper Jaffray CompaniesBoost Price TargetOverweight$380.00Medium
9/6/2018CowenBoost Price TargetOutperform ➝ Positive$315.00 ➝ $400.00Low
8/10/2018ArgusSet Price TargetBuy ➝ Buy$310.00 ➝ $372.00Medium
8/7/2018Morgan StanleyUpgradeUnderweight ➝ Equal Weight$210.00 ➝ $320.00Low
7/31/2018JPMorgan Chase & Co.Boost Price TargetOverweight$350.00Medium
7/31/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$345.00 ➝ $370.00High
7/31/2018Deutsche Bank AktiengesellschaftBoost Price TargetBuy ➝ Buy$280.00 ➝ $330.00High
7/31/2018CitigroupBoost Price TargetBuy ➝ Buy$330.00 ➝ $345.00High
7/31/2018BarclaysBoost Price TargetOverweight ➝ Overweight$300.00 ➝ $350.00High
7/31/2018Piper Jaffray CompaniesReiterated RatingPositive ➝ Overweight$350.00High
7/27/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$330.00 ➝ $340.00High
7/17/2018Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$272.00 ➝ $329.00Low
7/13/2018Morgan StanleyBoost Price TargetUnderweight$195.00 ➝ $210.00Medium
7/10/2018CowenBoost Price TargetOutperform ➝ Outperform$275.00 ➝ $315.00High
6/25/2018CitigroupBoost Price TargetBuy ➝ Buy$275.00 ➝ $330.00High
5/31/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$180.00 ➝ $195.00Low
5/29/2018Canaccord GenuityBoost Price TargetBuy ➝ Top Pick$270.00 ➝ $290.00Low
5/7/2018BarclaysUpgradeEqual Weight ➝ Overweight$235.00High
4/25/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$215.00 ➝ $235.00Medium
4/25/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$170.00 ➝ $180.00Medium
4/25/2018BTIG ResearchReiterated RatingHoldHigh
4/25/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$261.00 ➝ $271.00High
4/11/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$157.00 ➝ $170.00Low
2/5/2018CitigroupUpgradeNeutral ➝ Buy$260.00 ➝ $275.00High
1/31/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$200.00 ➝ $215.00Medium
1/31/2018CitigroupReiterated RatingHold$260.00Medium
1/31/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$145.00 ➝ $157.00High
1/31/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$250.00 ➝ $276.00High
1/31/2018Canaccord GenuityReiterated RatingBuy$255.00 ➝ $265.00High
1/31/2018First AnalysisUpgradeEqual Weight ➝ Overweight$277.00High
1/22/2018CowenBoost Price TargetOutperform$250.00 ➝ $275.00Low
1/16/2018BTIG ResearchReiterated RatingHoldLow
1/16/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$275.00Medium
1/9/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Positive$250.00 ➝ $260.00High
1/9/2018Piper Jaffray CompaniesReiterated RatingBuy$269.00N/A
1/5/2018William BlairDowngradeOutperform ➝ Market PerformMedium
1/5/2018BTIG ResearchInitiated CoverageNeutral ➝ NeutralHigh
1/4/2018Piper Jaffray CompaniesBoost Price TargetOverweight$274.00Medium
1/3/2018Evercore ISIInitiated CoverageOutperform$250.00Low
1/2/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$205.00Medium
12/14/2017Morgan StanleyBoost Price TargetUnderweight$122.00 ➝ $135.00Medium
10/25/2017CitigroupBoost Price TargetNeutral$180.00 ➝ $220.00N/A
10/25/2017BarclaysBoost Price TargetEqual Weight$150.00 ➝ $185.00N/A
10/25/2017Bank of AmericaBoost Price TargetBuy$215.00 ➝ $240.00N/A
10/25/2017Wells Fargo & CompanyReiterated RatingMarket Perform$200.00 ➝ $205.00N/A
10/25/2017Robert W. BairdUpgradeNeutral ➝ Outperform$184.00 ➝ $228.00N/A
10/23/2017Janney Montgomery ScottUpgradeSell ➝ NeutralN/A
10/23/2017Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$195.00 ➝ $160.00N/A
10/12/2017Canaccord GenuityReiterated RatingBuy$215.00 ➝ $230.00N/A
10/9/2017Piper Jaffray CompaniesReiterated RatingOverweight$202.00 ➝ $226.00N/A
9/26/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$200.00Low
9/13/2017ArgusBoost Price TargetBuy$205.00 ➝ $235.00Low
9/12/2017SVB LeerinkReiterated RatingOutperform$207.00 ➝ $225.00Low
8/9/2017BarclaysReiterated RatingEqual Weight$150.00Low
8/7/2017Canaccord GenuityUpgradeHold ➝ Buy$170.00 ➝ $215.00Medium
8/2/2017CowenReiterated RatingOutperform$200.00High
8/2/2017JPMorgan Chase & Co.Reiterated RatingOverweight$250.00High
8/2/2017First AnalysisUpgradeUnderweight ➝ Equal Weight$176.00High
7/28/2017Deutsche Bank AktiengesellschaftSet Price TargetHold$175.00Low
7/26/2017Canaccord GenuityReiterated RatingHold$170.00Medium
7/19/2017BarclaysReiterated RatingHold$150.00Low
7/10/2017Morgan StanleyReiterated RatingUnderweight$115.00 ➝ $122.00High
5/15/2017Morgan StanleyReiterated RatingUnderweight$108.00 ➝ $115.00Medium
4/29/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$165.00 ➝ $175.00Low
4/26/2017CowenReiterated RatingOutperform$200.00High
4/26/2017Cantor FitzgeraldBoost Price TargetNeutral ➝ Neutral$155.00 ➝ $170.00High
4/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$170.00 ➝ $187.00N/A
4/11/2017Bank of AmericaBoost Price TargetBuy$175.00 ➝ $195.00Low
4/5/2017SVB LeerinkReiterated RatingBuyMedium
3/20/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$195.00Medium
3/19/2017BTIG ResearchReiterated RatingHoldMedium
2/27/2017Evercore ISIUpgradeHold ➝ Buy$190.00N/A
2/21/2017Canaccord GenuityReiterated RatingHold$150.00N/A
2/9/2017SVB LeerinkBoost Price TargetMarket Perform$134.00 ➝ $138.00N/A
2/1/2017UBS GroupBoost Price TargetBuy$180.00 ➝ $185.00N/A
2/1/2017Cantor FitzgeraldReiterated RatingNeutral$155.00N/A
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$160.00N/A
1/12/2017Cantor FitzgeraldReiterated RatingNeutral$155.00N/A
1/12/2017Robert W. BairdReiterated RatingNeutral$147.00 ➝ $153.00N/A
1/11/2017CowenReiterated RatingOutperform$150.00N/A
1/11/2017SVB LeerinkReiterated RatingMarket Perform$114.00 ➝ $132.00N/A
1/10/2017Evercore ISIReiterated RatingHold$139.00N/A
1/10/2017Bank of AmericaUpgradeNeutral ➝ Buy$145.00 ➝ $175.00N/A
1/9/2017BarclaysReiterated RatingEqual Weight$145.00N/A
1/6/2017Janney Montgomery ScottReiterated RatingNeutral ➝ Sell$125.00N/A
1/6/2017CL KingUpgradeNeutral ➝ BuyN/A
12/7/2016Morgan StanleyLower Price TargetUnderweight$115.00 ➝ $100.00N/A
11/10/2016SVB LeerinkInitiated CoverageMarket Perform$145.00N/A
11/3/2016Cantor FitzgeraldReiterated RatingHold$155.00N/A
11/3/2016BTIG ResearchReiterated RatingHoldN/A
11/2/2016Canaccord GenuitySet Price TargetHold$135.00N/A
11/2/2016First AnalysisDowngradeEqual Weight ➝ Underweight$130.00 ➝ $116.00N/A
10/14/2016ArgusReiterated RatingBuy$205.00 ➝ $170.00N/A
10/12/2016CowenReiterated RatingOutperform$160.00N/A
10/12/2016Wells Fargo & CompanyReiterated RatingMarket Perform$150.00 ➝ $137.50N/A
10/12/2016BTIG ResearchReiterated RatingNeutralN/A
10/11/2016Canaccord GenuityLower Price TargetHold$165.00 ➝ $135.00N/A
10/11/2016BarclaysSet Price TargetEqual Weight$150.00 ➝ $142.00N/A
10/11/2016Cantor FitzgeraldLower Price TargetHold$165.00 ➝ $155.00N/A
10/11/2016Janney Montgomery ScottDowngradeNeutral ➝ Sell$155.00 ➝ $125.00N/A
10/11/2016CitigroupDowngradeBuy ➝ Neutral$190.00 ➝ $140.00N/A
10/7/2016Canaccord GenuitySet Price TargetHold$165.00 ➝ $136.00N/A
9/12/2016CitigroupBoost Price TargetBuy$175.00 ➝ $190.00N/A
8/22/2016CL KingDowngradeBuy ➝ NeutralN/A
8/16/2016UBS GroupReiterated RatingBuyN/A
8/8/2016ArgusBoost Price TargetBuy$175.00 ➝ $185.00N/A
7/28/2016UBS GroupReiterated RatingBuy$180.00N/A
7/27/2016JPMorgan Chase & Co.Boost Price TargetOverweight$185.00 ➝ $200.00N/A
7/27/2016Cantor FitzgeraldReiterated RatingHold$165.00N/A
7/27/2016MizuhoBoost Price TargetNeutral$138.00 ➝ $148.00N/A
7/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$161.00N/A
7/5/2016Morgan StanleyDowngradeEqual Weight ➝ Underweight$130.00 ➝ $110.00N/A
6/29/2016Cantor FitzgeraldReiterated RatingHoldN/A
(Data available from 6/23/2016 forward)
Illumina logo
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $469.13
Low: $464.21
High: $472.54

50 Day Range

MA: $410.38
Low: $372.84
High: $469.13

52 Week Range

Now: $469.13
Low: $260.42
High: $555.77


517,797 shs

Average Volume

1,031,120 shs

Market Capitalization

$68.49 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Illumina?

The following Wall Street sell-side analysts have issued research reports on Illumina in the last year: Argus, Atlantic Securities, Barclays PLC, BTIG Research, Canaccord Genuity, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Evercore ISI, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, OTR Global, Piper Sandler, Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, TheStreet, UBS Group AG, Wells Fargo & Company, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for ILMN.

What is the current price target for Illumina?

18 Wall Street analysts have set twelve-month price targets for Illumina in the last year. Their average twelve-month price target is $374.50, suggesting a possible downside of 20.2%. BTIG Research has the highest price target set, predicting ILMN will reach $570.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $280.00 for Illumina in the next year.
View the latest price targets for ILMN.

What is the current consensus analyst rating for Illumina?

Illumina currently has 4 sell ratings, 7 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ILMN, but not buy more shares or sell existing shares.
View the latest ratings for ILMN.

What other companies compete with Illumina?

How do I contact Illumina's investor relations team?

Illumina's physical mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company's listed phone number is 858-202-4500 and its investor relations email address is [email protected]com. The official website for Illumina is